Improvement of clinical outcomes and liver function in cirrhotic patients by selective COX-2 inhibitors: A retrospective study.
作者信息
Yang Zhu, Chen Ming, Tai Yang, Tong Huan, Huang Zhiyin, Gao Jinhang, Tang Chengwei
机构信息
Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Digestive Disease Institute, West China Clinical College, Chengdu, Sichuan 610041, China.
出版信息
Chin Med J (Engl). 2024 Dec 5;137(23):2871-2873. doi: 10.1097/CM9.0000000000003364. Epub 2024 Oct 30.
Abstract
摘要
相似文献
1
Improvement of clinical outcomes and liver function in cirrhotic patients by selective COX-2 inhibitors: A retrospective study.选择性COX-2抑制剂对肝硬化患者临床结局和肝功能的改善作用：一项回顾性研究。
Chin Med J (Engl). 2024 Dec 5;137(23):2871-2873. doi: 10.1097/CM9.0000000000003364. Epub 2024 Oct 30.
2
Sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers.窦状隙内皮细胞中COX-1衍生的前列腺素调节肝硬化大鼠肝脏的肝血管张力。
Am J Physiol Gastrointest Liver Physiol. 2005 Apr;288(4):G763-70. doi: 10.1152/ajpgi.00300.2004. Epub 2004 Nov 18.
3
Long-term intermittent oral administration of selective COX-2 inhibitor improved the clinical outcomes of COVID-19 in patients with cirrhosis.长期间断口服选择性 COX-2 抑制剂可改善肝硬化合并 COVID-19 患者的临床结局。
J Dig Dis. 2024 Aug;25(8):517-524. doi: 10.1111/1751-2980.13313. Epub 2024 Sep 30.
4
Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers.环氧化酶-1抑制可纠正肝硬化大鼠肝脏的内皮功能障碍。
J Hepatol. 2003 Oct;39(4):515-21. doi: 10.1016/s0168-8278(03)00347-7.
5
Selective cyclooxygenase-1 inhibition improves collateral vascular reactivity in biliary cirrhotic rats.选择性环氧化酶-1 抑制可改善胆汁性肝硬化大鼠的侧支血管反应性。
J Chin Med Assoc. 2013 Oct;76(10):557-63. doi: 10.1016/j.jcma.2013.06.006. Epub 2013 Jul 22.
6
Selective cyclooxygenase inhibition by SC-560 improves hepatopulmonary syndrome in cirrhotic rats.SC-560选择性抑制环氧化酶可改善肝硬化大鼠的肝肺综合征。
PLoS One. 2017 Jun 20;12(6):e0179809. doi: 10.1371/journal.pone.0179809. eCollection 2017.
7
The long-term outcomes of cirrhotic patients with pleural effusion.肝硬化合并胸腔积液患者的长期预后。
Saudi J Gastroenterol. 2018 Jan-Feb;24(1):46-51. doi: 10.4103/sjg.SJG_336_17.
8
Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites.
Gastroenterology. 1999 May;116(5):1167-75. doi: 10.1016/s0016-5085(99)70020-x.
9
Establishment of MELD-lactate clearance scoring system in predicting death risk of critically ill cirrhotic patients.MELD-乳酸清除评分系统的建立在预测危重症肝硬化患者死亡风险中的应用。
BMC Gastroenterol. 2022 Jun 3;22(1):280. doi: 10.1186/s12876-022-02351-5.
10
Correlation of microRNA-16, microRNA-21 and microRNA-101 expression with cyclooxygenase-2 expression and angiogenic factors in cirrhotic and noncirrhotic human hepatocellular carcinoma.微小RNA-16、微小RNA-21和微小RNA-101表达与环氧化酶-2表达及血管生成因子在肝硬化和非肝硬化人类肝细胞癌中的相关性
PLoS One. 2014 Apr 23;9(4):e95826. doi: 10.1371/journal.pone.0095826. eCollection 2014.
引用本文的文献
1
Arachidonic acid metabolism in metabolic dysfunction-associated steatotic liver disease and liver fibrosis.代谢功能障碍相关脂肪性肝病和肝纤维化中的花生四烯酸代谢
Hepatol Commun. 2025 Aug 29;9(9). doi: 10.1097/HC9.0000000000000802. eCollection 2025 Sep 1.
本文引用的文献
1
Inhibition of cyclooxygenase-2 alleviates liver cirrhosis via improvement of the dysfunctional gut-liver axis in rats.抑制环氧化酶-2可通过改善大鼠功能失调的肠-肝轴来减轻肝硬化。
Am J Physiol Gastrointest Liver Physiol. 2016 Jun 1;310(11):G962-72. doi: 10.1152/ajpgi.00428.2015. Epub 2016 Apr 7.
2
Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.肝细胞癌患者肝功能评估：一种基于新证据的方法——ALBI分级
J Clin Oncol. 2015 Feb 20;33(6):550-8. doi: 10.1200/JCO.2014.57.9151. Epub 2014 Dec 15.
3
Quality improvement guidelines for Transjugular Intrahepatic Portosystemic Shunt (TIPS).经颈静脉肝内门体分流术（TIPS）的质量改进指南。
Cardiovasc Intervent Radiol. 2012 Dec;35(6):1295-300. doi: 10.1007/s00270-012-0493-y. Epub 2012 Oct 16.
4
Clinical associations between arthritis and liver disease.关节炎与肝脏疾病之间的临床关联。
Ann Rheum Dis. 1982 Jun;41(3):295-307. doi: 10.1136/ard.41.3.295.
Zotero 插件